153 related articles for article (PubMed ID: 3716924)
1. An endogenous ligand for type II binding sites in normal and neoplastic tissues.
Clark JH; Markaverich BM
Adv Exp Med Biol; 1986; 196():305-15. PubMed ID: 3716924
[TBL] [Abstract][Full Text] [Related]
2. Preliminary characterization of an endogenous inhibitor of [3H]estradiol binding in rat uterine nuclei.
Markaverich BM; Roberts RR; Finney RW; Clark JH
J Biol Chem; 1983 Oct; 258(19):11663-71. PubMed ID: 6619136
[TBL] [Abstract][Full Text] [Related]
3. An endogenous inhibitor of [3H]estradiol binding to nuclear type II estrogen binding sites in normal and malignant tissues.
Markaverich BM; Roberts RR; Alejandro MA; Clark JH
Cancer Res; 1984 Apr; 44(4):1515-9. PubMed ID: 6704964
[TBL] [Abstract][Full Text] [Related]
4. Purification and characterization of nuclear type II [(3)H]estradiol binding sites from the rat uterus: covalent labeling with [(3)H]luteolin.
Markaverich BM; Shoulars K; Brown MA
Steroids; 2001 Sep; 66(9):707-19. PubMed ID: 11546559
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor binding to nuclei from normal and neoplastic rat mammary tissues in vitro.
Klinge CM; Bambara RA; Zain S; Hilf R
Cancer Res; 1987 Jun; 47(11):2852-9. PubMed ID: 3105869
[TBL] [Abstract][Full Text] [Related]
6. Preliminary characterization and partial purification of rat uterine nuclear type II Binding sites.
Markaverich BM; Gregory RR
Biochem Biophys Res Commun; 1991 Jun; 177(3):1283-90. PubMed ID: 2059216
[TBL] [Abstract][Full Text] [Related]
7. Nuclear binding of the estrogen receptor: heterogeneity of sites and uterotropic response.
Clark JH; Markaverich B; Upchurch S; Eriksson H; Hardin JW
Adv Exp Med Biol; 1979; 117():17-46. PubMed ID: 474276
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of nuclear estrogen-binding sites in the rat uterus: a simple method for the quantitation of type I and type II sites by [3H]estradiol exchange.
Markaverich BM; Williams M; Upchurch S; Clark JH
Endocrinology; 1981 Jul; 109(1):62-9. PubMed ID: 7238414
[TBL] [Abstract][Full Text] [Related]
9. Analysis of binding of [3H]Estradiol to the cytosol fraction of rat pancreas: comparison with sites in the cytosol of uterus.
Boctor AM; Band P; Grossman A
Endocrinology; 1983 Aug; 113(2):453-62. PubMed ID: 6872936
[TBL] [Abstract][Full Text] [Related]
10. Relationships between mammary estrogen receptor and estrogenic sensitivity. II. Binding of cytoplasmic receptor to chromatin.
Shyamala G; Singh RK; Ruh MF; Ruh TS
Endocrinology; 1986 Aug; 119(2):819-26. PubMed ID: 3732146
[TBL] [Abstract][Full Text] [Related]
11. Nuclease sensitivity of estradiol-charged estrogen receptor binding sites in nuclei isolated from normal and neoplastic rat mammary tissues.
Klinge CM; Bambara RA; Zain S; Hilf R
J Steroid Biochem; 1990 Jun; 36(1-2):7-14. PubMed ID: 2194077
[TBL] [Abstract][Full Text] [Related]
12. A simple modification of the estrogen receptor exchange assay: validation in nuclei from the rat uterus and a mouse mammary tumor.
Schoenberg DR; Clark JH
Endocrinology; 1980 Jan; 106(1):56-60. PubMed ID: 7349972
[TBL] [Abstract][Full Text] [Related]
13. Alterations in estrogen receptor isoforms in the mammary gland and uterus of the rat during differentiation.
Hyder SM; Wiehle RD; Wittliff JL
Comp Biochem Physiol B; 1988; 91(3):517-23. PubMed ID: 3233927
[TBL] [Abstract][Full Text] [Related]
14. Distribution of antiestrogen-specific binding sites in normal and neoplastic mammary gland.
Mehta RG; Cerny WL; Moon RC
Oncology; 1984; 41(6):387-92. PubMed ID: 6504492
[TBL] [Abstract][Full Text] [Related]
15. Cytosol type II sites in the rat uterus: interaction with an endogenous ligand.
Markaverich BM; Adams NR; Roberts RR; Alejandro M; Clark JH
J Steroid Biochem; 1987 Dec; 28(6):599-608. PubMed ID: 2826918
[TBL] [Abstract][Full Text] [Related]
16. Uterine type II estrogen-binding sites are not of eosinophil origin.
Markaverich BM; Roberts RR; Alejandro MA; Clark JH
J Biol Chem; 1986 Jan; 261(1):142-6. PubMed ID: 3941067
[TBL] [Abstract][Full Text] [Related]
17. Prolactin binding to mammary gland, 7,12-dimethylbenz(a)-anthracene-induced mammary tumors, and liver in rats.
Smith RD; Hilf R; Senior AE
Cancer Res; 1976 Oct; 36(10):3726-31. PubMed ID: 821605
[TBL] [Abstract][Full Text] [Related]
18. Methyl p-hydroxyphenyllactate. An inhibitor of cell growth and proliferation and an endogenous ligand for nuclear type-II binding sites.
Markaverich BM; Gregory RR; Alejandro MA; Clark JH; Johnson GA; Middleditch BS
J Biol Chem; 1988 May; 263(15):7203-10. PubMed ID: 3366774
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor activation in normal mammary gland.
Haslam SZ; Gale KJ; Dachtler SL
Endocrinology; 1984 Apr; 114(4):1163-72. PubMed ID: 6705732
[TBL] [Abstract][Full Text] [Related]
20. The effect of low dose continuous exposure to estradiol on the estrogen receptor (type I) and nuclear type II sites.
Markaverich BM; Roberts RR; Alejandro M; Clark JH
Endocrinology; 1984 Mar; 114(3):814-20. PubMed ID: 6697964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
